Effectiveness of the Japanese COVID-19 vaccine cannot be confirmed in trials
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
Effectiveness of the Japanese COVID-19 vaccine cannot be confirmed in trials
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Japan gets a bad news: Effectiveness of the Japanese COVID-19 vaccine cannot be confirmed in trials.
According to a report from Kyodo News on the 28th, AnGes, a Japanese pharmaceutical company from Osaka University, admitted that a COVID-19 vaccine it developed could not confirm its effectiveness in clinical trials.
Earlier this month, AnGes announced the results of vaccine clinical trials conducted on 560 people on its company homepage, stating that “the expected results have not been obtained” and “it is necessary to improve the effectiveness”.
According to Kyodo News, due to the inability to confirm the effectiveness in clinical trials, the launch of AnGes’ COVID-19 vaccine has also been postponed from 2021 to 2023.
Earlier, Japanese media pointed out that as early as March 2020, AnGes announced the start of the development of a COVID-19 vaccine, becoming the first company in Japan to start a COVID-19 vaccine clinical trial, and was once praised by Japanese media as a “Japanese vaccine pioneer.”
The founder of AnGes previously said in an interview with Taiwanese media: “I saw AstraZeneca’s supply contract with Japan and knew that the other party had the final say… Countries that cannot produce vaccines on their own are very miserable.”
Kyodo News said that the Japanese can now only hope that companies such as Shiono Yoshitaka, which were originally “half a beat”, will be the first to launch Japanese-made vaccines.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
